JP2024522904A5 - - Google Patents
Info
- Publication number
- JP2024522904A5 JP2024522904A5 JP2023580355A JP2023580355A JP2024522904A5 JP 2024522904 A5 JP2024522904 A5 JP 2024522904A5 JP 2023580355 A JP2023580355 A JP 2023580355A JP 2023580355 A JP2023580355 A JP 2023580355A JP 2024522904 A5 JP2024522904 A5 JP 2024522904A5
- Authority
- JP
- Japan
- Prior art keywords
- γglu
- human insulin
- desb30 human
- ethoxy
- docosanediacyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110709826.5 | 2021-06-25 | ||
| CN202110709826 | 2021-06-25 | ||
| PCT/CN2022/101204 WO2022268208A1 (zh) | 2021-06-25 | 2022-06-24 | 含酰化胰岛素的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522904A JP2024522904A (ja) | 2024-06-21 |
| JP2024522904A5 true JP2024522904A5 (https=) | 2025-06-23 |
Family
ID=84544235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580355A Pending JP2024522904A (ja) | 2021-06-25 | 2022-06-24 | アシル化インスリンを含む医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250262282A1 (https=) |
| EP (1) | EP4361174A4 (https=) |
| JP (1) | JP2024522904A (https=) |
| CN (1) | CN118139875A (https=) |
| AU (1) | AU2022300061A1 (https=) |
| CA (1) | CA3228912A1 (https=) |
| WO (1) | WO2022268208A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117561072A (zh) * | 2021-06-25 | 2024-02-13 | 甘李药业股份有限公司 | 含glp-1化合物的药物组合物 |
| CN116327890B (zh) * | 2023-05-29 | 2023-12-08 | 北京先为达生物科技有限公司 | 口服递送的组合物及其应用 |
| WO2025098457A1 (zh) * | 2023-11-07 | 2025-05-15 | 甘李药业股份有限公司 | 用于降糖的酰化胰岛素 |
| WO2025098502A1 (zh) * | 2023-11-08 | 2025-05-15 | 甘李药业股份有限公司 | 包含胰岛素衍生物的药物组合物的治疗用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2371361T3 (es) * | 2005-12-28 | 2011-12-30 | Novo Nordisk A/S | Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones. |
| CN101573133B (zh) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
| JP5688969B2 (ja) | 2007-07-16 | 2015-03-25 | ノボ・ノルデイスク・エー／エス | プロテアーゼに対して安定しているペグ化インスリンアナログ |
| BRPI0820535B8 (pt) * | 2007-11-16 | 2021-05-25 | Novo Nordisk As | composições farmacêuticas contendo insulina e um peptídeo insulinotrópico |
| WO2012080320A1 (en) * | 2010-12-14 | 2012-06-21 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| KR20140104994A (ko) | 2011-12-15 | 2014-08-29 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 인간 인슐린 유사체 및 이의 아실화 유도체 |
| CN104364260B (zh) * | 2012-04-11 | 2017-02-22 | 诺和诺德股份有限公司 | 胰岛素制剂 |
| CN104689302B (zh) * | 2015-02-05 | 2017-06-23 | 通化东宝药业股份有限公司 | 一种地特胰岛素注射液的制备方法及其制备的地特胰岛素注射液 |
| WO2018024186A1 (zh) | 2016-08-02 | 2018-02-08 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| PE20210857A1 (es) * | 2016-12-16 | 2021-05-18 | Novo Nordisk As | Composiciones farmaceuticas que contienen insulina |
| CN110386974B (zh) * | 2018-04-19 | 2022-12-09 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
| CN118754967A (zh) * | 2019-12-30 | 2024-10-11 | 甘李药业股份有限公司 | 胰岛素衍生物 |
-
2022
- 2022-06-24 AU AU2022300061A patent/AU2022300061A1/en active Pending
- 2022-06-24 CN CN202280044827.5A patent/CN118139875A/zh active Pending
- 2022-06-24 JP JP2023580355A patent/JP2024522904A/ja active Pending
- 2022-06-24 US US18/571,461 patent/US20250262282A1/en active Pending
- 2022-06-24 EP EP22827700.0A patent/EP4361174A4/en active Pending
- 2022-06-24 WO PCT/CN2022/101204 patent/WO2022268208A1/zh not_active Ceased
- 2022-06-24 CA CA3228912A patent/CA3228912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522904A5 (https=) | ||
| US12576136B2 (en) | Insulin derivative | |
| JP5562510B2 (ja) | 修飾ｇｌｐ−１の安定な処方剤 | |
| CN114901680A (zh) | 长效glp-1化合物 | |
| KR102161177B1 (ko) | 지속형 인슐린분비 펩타이드 결합체 액상 제제 | |
| JP2023510206A5 (https=) | ||
| CN103491975A (zh) | 酰化胰高血糖素类似物与胰岛素类似物的组合 | |
| JP2001011095A (ja) | Ｇｌｐ−１誘導体 | |
| JP2007537142A (ja) | アルブミン様物質に結合した新規のｇｌｐ−１類似物 | |
| JP2003522099A (ja) | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン | |
| JP2009532422A (ja) | Ｇｌｐ−１ペプチドアゴニスト | |
| US20250262282A1 (en) | Acylated Insulin-Containing Pharmaceutical Composition | |
| US20190338008A1 (en) | Long-acting co-agonists of the glucagon and glp-1 receptors | |
| US20230063794A1 (en) | Stapled triazole co-agonists of the glucagon and glp-1 receptors | |
| EP4081244B1 (en) | Stapled olefin co-agonists of the glucagon and glp-1 receptors | |
| AU2020415355A1 (en) | Stapled lactam co-agonists of the glucagon and GLP-1 receptors | |
| HK40070502A (zh) | 胰岛素衍生物 | |
| HK1193042A (en) | Combination of acylated glucagon analogues with insulin analogues |